CTIS2022-502724-46-00进行中（未招募）1 期
A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects with Chronic Hepatitis B Infection, Including Subjects with Chronic Hepatitis D Infection - BJT-778-001
Bluejay Therapeutics Inc.0 个研究点目标入组 84 人开始时间: 2023年3月31日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Cohorts B through F: Able and willing to provide written informed consent (signed and dated) and any authorizations required by local law and can comply with all study requirements, Cohorts D and F only: Must have quantifiable HDV ribonucleic acid (RNA) levels, Male or female adults between 18 and 70 years of age, BMI 18 to 40 kg/m2, Chronic HBV infection =6 months (eg, positive for serum HBsAg =6 months), Plasma HBV deoxyribonucleic acid (DNA) <100 IU/mL at Scree, On nucleos(t)ide analogs (entecavir, tenofovir disoproxil, or tenofovir alafenamide) for at least 2 months and willing to remain on stable treatment for the duration of the study, Quantitative HBsAg level criteria at Screening by cohort/group: o Cohort B: =10 to =3000 IU/mL o Cohort C: >3000 IU/mL o Cohort D: =10 IU/mL o Cohorts E and F: =10 IU/mL, Females: Nonpregnant and nonlactating; surgically sterile (eg, tubal ligation, hysterectomy, bilateral salpingectomy, bilateral oophorectomy), postmenopausal (defined as 12 months of spontaneous amenorrhea in females >55 years of age or, in females =55 years of age, 12 months of spontaneous amenorrhea without an alternative medical cause and FSH levels in the postmenopausal range for the laboratory involved) or, if engaged in sexual relations and of childbearing potential, subject is using an acceptable contraceptive method from the time of signing the informed consent form until at least 12 weeks after the last dose of study drug., Males: Surgically sterile or, if engaged in sexual relations with a female of childbearing potential, subject is utilizing an acceptable contraceptive method during treatment with study drug and for at least 12 weeks after the last dose of study drug. Agree not to donate sperm for at least 12 weeks after the last dose of study drug.
排除标准
- •Cohorts B through F: Evidence of cirrhosis as determined by any of the following: o Liver biopsy (ie,Metavir Score F4) within 1 year of Screening, or o Fibroscan =10.8 Kpa within 1 year of Screening, Screening laboratory results as follows, or any other clinically significant abnormalities in screening laboratory values that would render a subject unsuitable for inclusion: o ALT or aspartate aminotransferase (AST) >3× upper limit of normal (ULN) o Total bilirubin >1.2× ULN, except for subjects with Gilbert’s (normal direct bilirubin) o Serum albumin <3.5 g/dL o International normalized ratio (INR) >1.2 o Platelet count <140 k/mm3 o Hemoglobin <12.0 g/dL for males and <11.0 g/dL for females o Absolute neutrophil count <1500/mm3 o Estimated glomerular filtration rate (eGFR) <50 mL/min/1.73 m2 by Modification of Diet in Renal Disease II o Positive test for blood on urinalysis. In the event of a positive test, eligibility may be confirmed with urine microscopy showing <5 red blood cells per high power field, Clinically significant abnormalities aside from chronic HBV infection in medical history (eg, previous acute coronary syndrome within 6 months of Screening, major surgery within 3 months of Screening, uncontrolled diabetes) or physical examination, History of bleeding diathesis or coagulopathy, History or suspected presence of vasculitis, History of extrahepatic disorders possibly related to HBV immune complexes (eg, glomerulonephritis, polyarteritis nodosa), Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated, Treatment with a different investigational drug other than BJT-778, a biological agent or device within 4 weeks or 5 half-lives of Screening, whichever is longer, History of excess alcohol consumption within 1 year of Screening, defined as weekly intake of =14 drinks per week (average of =2 drinks per day), History of drug abuse/addiction within 6 months of Screening (except cannabis) or a positive drug test at Screening (excluding physician-prescribed drugs and cannabis), Unwillingness to comply with study procedures, including follow up, as specified by this protocol, or unwillingness to cooperate fully with the Investigator, History of decompensated liver disease as evidenced by ascites, hepatic encephalopathy, and/or gastric or esophageal varices, Have any other conditions (medical, social, psychiatric, or other), which in the opinion of the Investigator would make the subject unsuitable for inclusion, or could interfere with the subject participating in or completing the study, Positive rapid antigen test for COVID-19 on Study Day 1, Cohorts B, C, and E only: Positive HDV Ab, History of liver disease other than Hepatitis B (ie, nonalcoholic steatohepatitis, alcohol associated hepatitis, cholestatic liver disease, etc.), Chronic HCV infection; subjects with past HCV RNA infection that was successfully treated must be HCV RNA negative and at least 24 weeks post-treatment, HIV infection (Cohorts B, C, and E); well-controlled HIV infection will be allowed in Cohorts D and F, defined as on antiretroviral therapy for at least 6 months and HIV RNA below the limit of quantification with a CD4 count =400 cells/mm3 at Screening, Received solid organ or bone marrow transplant, Currently taking, or took within 1 month of Screening, any immunosuppressive drugs (eg, prednisone). If the subject received a short course, the situation may be
研究者
相似试验
招募中
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of BJT-778 in Subjects with Chronic HBV Infection (CHB).Chronic Hepatitis B Virus (HBV) InfectionInfection - Other infectious diseasesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12623000078651Bluejay Therapeutics Inc.40
招募中
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Subjects with Chronic HBV Infection (CHB) and Chronic HDV Infection (CHD).ACTRN12623000105640Bluejay Therapeutics Inc.32
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers.Chronic Hepatitis B Virus (HBV) InfectionChronic Hepatitis D Virus (HDV) InfectionInfection - Other infectious diseasesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12623000075684Bluejay Therapeutics Inc23
尚未招募
2 期
An optional multicenter, open-label Phase 2a multiple dose study in Chronic Hepatitis B (CHB) subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778ACTRN12623000111673Bluejay Therapeutics Inc.24
已完成
2 期
A study of the safety of combining BIT225 with pegylated interferon and ribavirin, in patients with hepatitis C virus infection, including measurement of the concentration and distribution of BIT225 in the body and antiviral activity.Hepatitis C Virus InfectionInfection - Other infectious diseasesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12612000828820Biotron Limited24